Riccardo Asteggiano
Research Subjects
Riccardo Asteggiano has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Victor Aboyans
Department of Cardiology, Princess Grace Hospital , 1, Ave Pasteur, Monaco 98000
2 shared publications Antonella Fava
Cardiovascular and Thoracic Department, Division of Cardiology, “Città della Salute e della Scienza” Hospital, Turin, Italy
1 shared publicationDimitrios J Richter
Second Cardiac Department, Euroclinic Hospital, Athens, Greece
1 shared publication- Dimitrios Richter
Head Cardiac Department, Euroclinic Hospital, Athens, Greece
1 shared publication Elena Coletti Moia
LARC-Laboratorio Analisi e Ricerca Clinica, Turin, Italy
1 shared publication- Geraldine Lee
Catherine McAuley School of Nursing & Midwifery, Brookfield Health Sciences Complex, University College Cork, Cork, Ireland
1 shared publication
Latest Publications
- 21 February 2023
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 78 (4) , 1-3
Comment to the article: ‘left atrial phasic volumes and functions changes in asymptomatic patients with sarcoidosis: evaluation by three-dimensional echocardiography’
The paper ‘Left atrial phasic volumes and functions changes in asymptomatic patients with sarcoidosis: evaluation by three-dimensional echocardiography’ is interesting and deserves the right consid...
- 21 February 2023
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 78 (4) , 1-3
Comment to the article: ‘left atrial phasic volumes and functions changes in asymptomatic patients with sarcoidosis: evaluation by three-dimensional echocardiography’
The paper ‘Left atrial phasic volumes and functions changes in asymptomatic patients with sarcoidosis: evaluation by three-dimensional echocardiography’ is interesting and deserves the right consid...
- Open Access
- 7 January 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (2) , 205-206
Cardiology care delivered to cancer patients
Survival of patients with cancer has increased substantially nowadays, thanks to the progress in treatments. As a result, patients can then exhibit some long-term cardiovascular (CV) system effects from their oncology treatments.
- 7 January 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (2) , 205-206
Open AccessCardiology care delivered to cancer patients
Survival of patients with cancer has increased substantially nowadays, thanks to the progress in treatments. As a result, patients can then exhibit some long-term cardiovascular (CV) system effects from their oncology treatments.
- Open Access
- 27 February 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (9) , 723-724
Cardiologists and management of vascular diseases
Survey shows that younger cardiologists in Europe do not screen for peripheral arterial diseases in patients as frequently as do their older contemporaries
- 27 February 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (9) , 723-724
Open AccessCardiologists and management of vascular diseases
Survey shows that younger cardiologists in Europe do not screen for peripheral arterial diseases in patients as frequently as do their older contemporaries
- 23 February 2018
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 25 (6) , 608-617
European Society of Cardiology Council for Cardiology Practice worldwide survey of transcatheter aortic valve implantation beliefs and practices
Transcatheter aortic valve implantation (TAVI) continues to gain popularity in the management of patients with severe aortic stenosis (SAS). Distribution of resources to maximise appropriate use remains a priority. To determine the current perceptions and behaviours regarding SAS patient management, an 18-point multiple-choice questionnaire was distributed to European Society of Cardiology (ESC) Council for Cardiology Practice (CCP) e-journal and/or electronic newsletter subscribers. Respondents to all questions were considered. Sub-analyses based on respondent age, practice setting and geographical location were performed. Of 1245 full respondents, 41.5% were aged ≥ 51 years, 22.7% were aged 41–50 years and 35.8% were aged ≤ 40 years. The majority were located in Europe (77.5%), followed by Asia/Oceania (11.6%), America (7.6%) and Africa (3.4%). In-hospital and out-of-hospital cardiologists accounted for 57.4% of and 28.5% of the sample, respectively, with the remainder being general practitioners/other. The majority of respondents (70.1%) claimed to diagnose between one and five cases of SAS per month. Free access to TAVI was reported by 41.2%, being less common for those aged ≤ 40 years (32.7%; p < 0.001), those located in Asia/Oceania, America and Africa (20.1%, 18.1% and 2.4%, respectively; p < 0.01 in each case) and in-hospital compared to out-of-hospital cardiologists (35.7% vs. 54.5%, respectively; p < 0.001). The most common reason for not referring a patient for an aortic valve intervention was assessment that the patient was high risk/non-operable (55.5%), followed by short life expectancy (30.5%). The most common reason for referring a patient for TAVI over surgical replacement was surgical risk score (56.9%). The most commonly perceived main complication of TAVI was stroke (28.9%), while the most frequently selected main benefit was improvement in quality of life (37.2%). A high proportion (82.5%) of respondents believed that TAVI is/may become a viable option for lower-risk SAS patients in future. The population of potential TAVI is significant worldwide, with key barriers to referral being access limitations and poor physician education. Strategies to minimise these factors are paramount.
- 23 February 2018
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 25 (6) , 608-617
European Society of Cardiology Council for Cardiology Practice worldwide survey of transcatheter aortic valve implantation beliefs and practices
Transcatheter aortic valve implantation (TAVI) continues to gain popularity in the management of patients with severe aortic stenosis (SAS). Distribution of resources to maximise appropriate use remains a priority. To determine the current perceptions and behaviours regarding SAS patient management, an 18-point multiple-choice questionnaire was distributed to European Society of Cardiology (ESC) Council for Cardiology Practice (CCP) e-journal and/or electronic newsletter subscribers. Respondents to all questions were considered. Sub-analyses based on respondent age, practice setting and geographical location were performed. Of 1245 full respondents, 41.5% were aged ≥ 51 years, 22.7% were aged 41–50 years and 35.8% were aged ≤ 40 years. The majority were located in Europe (77.5%), followed by Asia/Oceania (11.6%), America (7.6%) and Africa (3.4%). In-hospital and out-of-hospital cardiologists accounted for 57.4% of and 28.5% of the sample, respectively, with the remainder being general practitioners/other. The majority of respondents (70.1%) claimed to diagnose between one and five cases of SAS per month. Free access to TAVI was reported by 41.2%, being less common for those aged ≤ 40 years (32.7%; p < 0.001), those located in Asia/Oceania, America and Africa (20.1%, 18.1% and 2.4%, respectively; p < 0.01 in each case) and in-hospital compared to out-of-hospital cardiologists (35.7% vs. 54.5%, respectively; p < 0.001). The most common reason for not referring a patient for an aortic valve intervention was assessment that the patient was high risk/non-operable (55.5%), followed by short life expectancy (30.5%). The most common reason for referring a patient for TAVI over surgical replacement was surgical risk score (56.9%). The most commonly perceived main complication of TAVI was stroke (28.9%), while the most frequently selected main benefit was improvement in quality of life (37.2%). A high proportion (82.5%) of respondents believed that TAVI is/may become a viable option for lower-risk SAS patients in future. The population of potential TAVI is significant worldwide, with key barriers to referral being access limitations and poor physician education. Strategies to minimise these factors are paramount.
- 1 January 2015
- Published by Springer Nature
- p. 23-97
Physiopathology and Toxic Heart Effects of Chemotherapy Drugs
- 1 January 2015
- Published by Springer Nature
- p. 23-97
Physiopathology and Toxic Heart Effects of Chemotherapy Drugs
- 1 January 2015
- Published by Springer Nature
- p. 99-127
Radiotherapy Heart Effects
- 1 January 2015
- Published by Springer Nature
- p. 1-21
Introduction